Immunovant has priced an underwritten common stock offering of 26.2 million shares at $21.00 per share, raising approximately $550 million in gross proceeds. The company expects existing cash plus the proceeds to fund operating expenses and capital expenditures through a potential commercial launch of IMVT-1402 for Graves' disease. Roivant Sciences, Immunovant's controlling stockholder, has agreed to purchase shares in the offering. Leerink Partners is acting as sole underwriter. The offering is expected to close on or about 12 December 2025, subject to customary closing conditions. The shares are being offered pursuant to an automatic registration statement on Form S-3 previously filed with the Securities and Exchange Commission.

Watertown, MA, December 10, 2025 — PsiThera, a biotech company harnessing biologically relevant protein states and computational intelligence to create oral drugs for diseases long-constrained by injectable-only approaches, announced today that it has closed a $47.5 million Series A financing and appointed Eric Shaff as Chief Executive Officer. The equity round was led by Samsara Biocapital…